EDAP TMS Retains CG Capital as New Investor Relations Counsel
December 12 2016 - 7:30AM
EDAP TMS S.A. (NASDAQ:EDAP), the global leader in therapeutic
ultrasound today announced that it has retained CG Capital, a
leading capital markets development and research firm as their new
investor relations counsel.
Marc Oczachowski, EDAP TMS Chief Executive Officer, commented,
"CG Capital's expertise, contacts and strategic counsel in investor
relations and in the healthcare sector will add significant value
to our efforts to increase visibility within the financial and
medical community. We look forward to leveraging their expertise as
we continue to expand our activities bringing to U.S. patients our
innovative therapeutic solutions."
"We will continue to develop EDAP TMS’ investor relations
program," said Rich Cockrell, President of CG Capital. "I believe
that EDAP TMS’ technology represents a compelling investment idea
and we look forward to increasing the Company’s visibility through
the introduction to new investors. I am confident that our firm
will execute well on behalf of EDAP TMS’ shareholders."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters’ range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
About CG Capital
CG Capital is a capital markets development firm focused on
enhancing investor awareness for small-to-midcap companies. It
aligns a company's strategic goals to an institution's investment
thesis and fundamentals to create a sound, long-term investment
objective. The company also advises companies in various areas,
including private and pre-IPO activity, mergers and acquisitions,
bankruptcy, executive transitions, activist shareholders, hostile
takeovers, downsizing, and event management.
www.cg.capital.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management’s current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company’s filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company’s Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
CG CAPITAL
877.889.1972
investorrelations@cg.capital
www.cg.capital
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Apr 2023 to Apr 2024